Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bengbu
Clinical trial register · China

Clinical Trials in Bengbu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca34 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.11 The First Affiliated Hospital of Bengbu Medical University10 Merck Sharp & Dohme LLC6 Eli Lilly and Company5
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Bengbu

219 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Nanjing Leads Biolabs Co.,Ltd
Phase 3
280
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2026-11-16
Recruiting
AstraZeneca
Phase 3
140
Beijing, Bengbu, Changchun, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou
2026-10-09
Recruiting
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation), Finerenone
DrugFinerenone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
2,832
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zhengzhou
2026-10-09
Recruiting
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases
Antengene Biologics Limited
Phase 1
149
Bengbu, Hefei, Beijing, Xiamen, Guangzhou, Luoyang, Zhengzhou, Wuhan
2026-09-26
Recruiting
AstraZeneca
Phase 3
286
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2026-09-17
Recruiting
Antengene Biologics Limited
Phase 3
380
Bengbu, Fuyang, Hefei, Beijing, Chongqi, Fuzhou, Lanzhou, Wuwei
2026-09-17
Recruiting
Vividion Therapeutics, Inc.
Phase 2
140
Bengbu, Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Jinan, Shanghai
2026-09-11
Recruiting
AstraZeneca
Phase 3
417
Beijing, Bengbu, Changchun, Changde, Changlexi, Changsha, Chengdu, Dalian
2026-08-31
Recruiting
Ocumension Therapeutics (Suzhou) Co., Ltd
Phase 3
842
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou
2026-08-25
Not yet open
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
309
Bengbu, Wuhu, Fuzhou, Xiamen, Guangzhou, Shenzhen, Haikou, Baoding
2026-08-24
Not yet open
First Affiliated Hospital of Wannan Medical College
Not applicable
20
Wuhu, Bengbu
2026-08-01
Not yet open
Papaverine and Sublingual Microcirculation in Septic Shock
NCT07657741Septic Shock, Microcirculatory Dysfunction, Sublingual Microcirculation, Hemodynamic Instability
DrugPapaverine
First Affiliated Hospital of Wannan Medical College
Not applicable
20
Bengbu, Wuhu
2026-08-01
Not yet open
First Affiliated Hospital of Wannan Medical College
Not applicable
20
Bengbu, Wuhu
2026-08-01
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
48
Bengbu, Beijing, Chongqing, Foshan, Guangzhou, Shenzhen, Zhuhai, Shijiazhuang
2026-07-21
Recruiting
InventisBio Co., Ltd
Phase 1
24
Bengbu
2026-07-17
Active, closed
Affiliated Hospital of Nantong University
Not applicable
100
Bengbu, Nantong, Hangzhou
2026-07-14
Not yet open
Jiangsu Carephar Pharmaceutical Co., Ltd.
Phase 2
156
Beijing, Bengbu, Changsha, Chongqing, Fujian, Guangzhou, Hefei, Huizhou
2026-07-12
Recruiting
Climb Bio, Inc.
Phase 1/2
30
Mianyang, Baoji, Beijing, Bengbu, Changsha, Hefei, Nanchang, Suzhou
2026-06-30
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
198
Bengbu, Bozhou, Beijing, Chongqing, Lanzhou, Guangzhou, Jiangmen, Shenzhen
2026-06-22
Recruiting
TCRx Therapeutics Co.Ltd
Observational
200
Bengbu, Hefei
2026-06-22
Recruiting
China Metastatic Liver Cancer Clinical Registry Cohort Database
NCT07602504Liver Metastases, Metastases to Liver, Liver Cancer, Neoplasms
Anhui Provincial Hospital
Observational
2,000
Bengbu, Hefei, Qingdao
2026-06-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
260
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Zhanjiang, Nanning
2026-06
Recruiting
Shanghai Henlius Biotech
Phase 1
258
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou
2026-05-25
Recruiting
BeOne Medicines
Phase 3
1,056
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning
2026-05-22
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Nanjing, Shanghai, Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou
2026-05-21
Recruiting
Huahui Health
Phase 1/2
30
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou
2026-05-19
Recruiting
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
NCT07632677Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
10,000
Bengbu, Hefei, Wuhu, Guangzhou, Shenzhen, Nanning, Zunyi, Haikou
2026-05-15
Recruiting
The First Affiliated Hospital of Bengbu Medical University
Phase 2
38
Bengbu
2026-05-01
Recruiting
AstraZeneca
Phase 3
230
Beijing, Bengbu, Cangzhou, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2026-04-24
Recruiting
Boehringer Ingelheim
Phase 3
670
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-04-13
Recruiting
Eisai Co., Ltd.
Phase 2
256
Bengbu, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Guiyang, Luoyang
2026-03-31
Recruiting
TJ Biopharma Co., Ltd.
Phase 2
170
Bengbu, Chongqing, Jiangmen, Zhongshan, Guilin, Nanning, Langfang, Shijiazhuang
2026-03-26
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
440
Anqing, Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2026-03-24
By invitation
The First Affiliated Hospital of Bengbu Medical University
Not applicable
378
Bengbu
2026-03-24
Recruiting
Hutchmed
Phase 3
240
Shanghai, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing
2026-03-20
Recruiting
Takeda
Phase 3
1,182
Bengbu, Beijing, Guangzhou, Wuhan, Zhuzhou, Baotou Shi, Pingxiang, Linyi Shi
2026-03-11
Not yet open
Dermavon Holdings Limited
Phase 2/3
540
Bengbu, Wuhu, Guangzhou, Chengde, Handan, Shijiazhuang, Harbin, Nanyang
2026-03-03
Not yet open
Sir Run Run Shaw Hospital
Not applicable
206
Bengbu, Beijing, Nanning, Haikou, Zhengzhou, Zhoukou, Chenzhou, Huai'an
2026-03
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
344
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Luoyang
2026-02-13
Recruiting
Eli Lilly and Company
Phase 3
900
Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan
2026-02-09
Recruiting
Nanjing Legend Biotech Co.
Phase 1
38
Bengbu, Guangzhou, Changsha, Xuzhou, Nanchang
2026-01-29
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
190
Bengbu, Chaoyang, Fuzhou, Guandong, Harbin, Wuhan, Changsha, Nanchang
2026-01-26
Recruiting
The First Affiliated Hospital of Bengbu Medical University
Not applicable
60
Bengbu
2026-01-25
Recruiting
The First Affiliated Hospital of Bengbu Medical University
Not applicable
120
Bengbu
2026-01-01
Not yet open
KN5501 Cell Injection for Refractory SLE(CLEAR)
NCT07358988Systemic Lupus Erthematosus (SLE)
Ruitherapeutics Co., LTD
Phase 1
36
Bengbu, Beijing, Luoyang, Wuhan, Nanjing, Shanghai
2026-01
Recruiting
AstraZeneca
Phase 3
1,100
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-12-29
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1
117
Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan
2025-12-16
Recruiting
JHM BioPharma (Tonghua) Co. , Ltd.
Phase 3
207
Bengbu, Hefei, Beijing, Chongqing, Guangzhou, Nanning, Cangzhou, Shijiazhuang
2025-12-11
Active, closed
Zai Lab (Shanghai) Co., Ltd.
Phase 3
108
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou
2025-12-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou
2025-12-03
Recruiting
Shanghai Henlius Biotech
Phase 1
246
Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou
2025-11-25
Recruiting
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07236762Systemic Lupus Erythematosus, Lupus Nephritis (LN), Sjogren's Syndrome, Inflammatory Myopathy
DrugYTS109 cell
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
18
Bengbu
2025-11-24
Active, closed
Qilu Pharmaceutical Co., Ltd.
Phase 3
146
Bengbu, Beijing, Chongqing, Lanzhou, Haikou, Zhengzhou, Changsha, Nanjing
2025-11-21
Recruiting
Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial
NCT07648693Transcatheter Aortic Valve Replacement (TAVR), Cerebral Vascular Accident (CVA)/Stroke
Resonova (Shanghai) Medtech Limited
Not applicable
240
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanchang, Qingdao
2025-10-31
Recruiting
Dynamic Airway Resistance & ML: Guide Sputum Suction in Ventilated Patients
NCT07375667Mechanical Ventilation Pressure High, Ventilator-Associated Pneumonia (VAP), Respiratory Depression Neonatal
Affiliated Hospital of Nantong University
Not applicable
258
Bengbu, Beijing, Hangzhou
2025-10-30
Recruiting
Hoffmann-La Roche
Phase 3
600
Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou
2025-10-24
Recruiting
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
NCT07095075Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.
Early Phase 1
36
Bengbu, Hefei, Nanjing, Suzhou, Wenzhou
2025-10-14
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan
2025-09-30
Recruiting
Merck Sharp & Dohme LLC
Phase 2
315
Bengbu, Beijing, Guangzhou, Luoyang, Pingxiang, Changchun, Ürümqi, Kunming
2025-09-26
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin
2025-09-22
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Active, closed
Shanghai TTM-Bio Technology Co., Ltd
Phase 1
64
Bengbu, Shanghai
2025-09-06
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
416
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen
2025-07-25
Active, closed
Amgen
Phase 3
12,800
Bengbu, Beijing, Guangzhou, Huizhou, Yulin, Qinhuangdao, Shijiazhuang, Harbin
2025-07-25
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
246
Bengbu, Hefei, Beijing, Fuzhou, Lanzhou, Jiangmen, Nanning, Guiyang
2025-07-07
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
985
Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning
2025-06-05
Recruiting
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 1/2
56
Bengbu, Beijing, Tangshan, Zhengzhou, Nanchang, Xi’an, Tianjin
2025-05-12
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Bengbu, Hefei, Beijing, Chongqing, Fuzhou Fujian, Xiamen, Guangzhou, Shantou
2025-04-24
Recruiting
BioNTech SE
Phase 1/2
380
Bengbu, Changchun, Chengdu, Chongqing, Huizhou, Nanning, Shanghai, Xi'an
2025-04-23
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
90
Bengbu, Ma’anshan, Beijing, Fuzhou, Quanzhou, Lanzhou, Guangzhou, Liuzhou
2025-04-23
Recruiting
AstraZeneca
Phase 3
830
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2025-04-10
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
Bengbu, Beijing, Guangzhou, Liuzhou, Xingtai, Luoyang, Changsha, Wuhan
2025-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Bengbu, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Wuhan, Xiangyang
2025-03-16
Active, closed
Takeda
Phase 3
601
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Luoyang, Wuhan, Zhuzhou
2025-03-10
Recruiting
AstraZeneca
Phase 3
840
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou
2025-03-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
120
Bengbu, Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Langfang
2025-03
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Bengbu, Jiangmen, Xingtai, Harbin, Luohe, Changsha, Nanjing, Nantong
2025-02-20
Recruiting
BioNTech SE
Phase 3
621
Changchun, Baoding, Beijing, Bengbu, Fuzhou, Guangzhou, Hangzhou, Ha’erbin
2025-02-03
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
135
Bengbu, Wuwei, Guangzhou, Huizhou, Harbin, Luoyang, Nanyang, Zhengzhou
2025-01-28
Active, closed
argenx
Phase 3
631
Bengbu, Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Luoyang, Xinxiang
2025-01-15
Recruiting
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Recruiting
BioNTech SE
Phase 2/3
1,580
Baoding, Beijing, Bengbu, Changchun, Changsha, Hangzhou, Jiamusi, Jinan
2025-01-07
Recruiting
Anhui Provincial Hospital
Observational
10,000
Anqing, Bengbu, Bozhou, Chizhou, Chuzhou, Fuyang, Hefei, Huaibei
2025-01-01
Not yet open
InnoBM Pharmaceuticals Co., Ltd.
Phase 3
228
Bengbu, Anyang, Zhengzhou, Nanjing, Lishui, Guangzhou, Lanzhou, Luoyang
2025-01
Recruiting
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
420
Bengbu, Wuhu, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhanjiang, Huizhou
2024-12-23
Recruiting
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Phase 1
123
Bengbu, Shanghai, Hangzhou
2024-12-16
Recruiting
Basilea Pharmaceutica
Phase 3
450
Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang
2024-12-11
Recruiting
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Active, closed
AstraZeneca
Phase 2/3
432
Baotou, Beijing, Bengbu, Changchun, Changde, Changsha, Changzhou, Chengdu
2024-12-06
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Baise City, Beijing, Bengbu, Changchun, Changsha, Changzhi, Changzhou, Chengdu
2024-11-22
Recruiting
UCB Biopharma SRL
Phase 3
450
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou
2024-11-21
Active, closed
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
482
Bengbu, Hefei, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou
2024-11-14
Recruiting
Capital Medical University
Phase 3
1,184
Bengbu, Bozhou, Huaibei, Suzhou, Beijing, Haidian, Pinggu, Tongzhou
2024-11-07
Not yet open
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Anqing, Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Quanzhou
2024-11-07
By invitation
The First Affiliated Hospital of Bengbu Medical University
Not applicable
200
Bengbu
2024-10-20
Recruiting
argenx
Phase 3
69
Beijing, Bengbu, Chengde, Hohhot, Huai'an, Huizhou, Tianjin, Wuhan
2024-10-18
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
542
Bengbu, Hefei, Beijing, Quanzhou, Zhangzhou, Lanzhou, Wuwei, Guangzhou
2024-10-11
Active, closed
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
500
Bengbu, Tongling, Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen
2024-10-08
Active, closed
AstraZeneca
Phase 3
768
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Deyang, Ganzhou
2024-10-04
Active, closed
AstraZeneca
Phase 3
293
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Deyang
2024-09-26
Recruiting
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
NCT06548607SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
DrugCD19
Nanjing Bioheng Biotech Co., Ltd.
Early Phase 1
20
Bengbu
2024-09-14
Recruiting
Heronova Pharmaceuticals
Phase 1/2
60
Bengbu, Changsha
2024-09-11
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan
2024-08-22
Recruiting
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
NCT04974138Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
DrugsAmlodipine besylate and folic acid·Amlodipine besylate·Amlodipine
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
32,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
24,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
AstraZeneca
Phase 3
620
Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Fuzhou
2024-08-12
Recruiting
AstraZeneca
Phase 3
788
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2024-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Bengbu, Hefei, Beijing, Chongqing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang
2024-07-16
Recruiting
NGGT (Suzhou) Biotechnology Co., Ltd.
Phase 1/2
18
Bengbu, Shanghai
2024-07-16
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2
90
Beijing, Bengbu, Changsha, Fuzhou, Guangzhou, Jinan, Kunming, Nanning
2024-07-11
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Bengbu, Hefei, Lu'an, Wuhu, Beijing, Fuzhou, Lanzhou, Dongguan
2024-06-30
Active, closed
Biotheus Inc.
Phase 3
392
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou
2024-06-11
Recruiting
InnoCare Pharma Inc.
Phase 3
476
Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2024-05-29
Recruiting
AstraZeneca
Phase 3
440
Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou
2024-05-20
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
226
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-05-15
Recruiting
Eli Lilly and Company
Phase 3
510
Beijing, Bengbu, Changsha, Chengdu, Foshan, Fuzhou, Guangdong, Haikou
2024-04-29
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
138
Bengbu, Beijing, Chengde, Harbin, Zhengzhou, Wuhan, Zhuzhou, Shenyang
2024-04-17
Recruiting
Ascentage Pharma Group Inc.
Phase 3
344
Bengbu, Guangzhou, Zhanjiang, Zhengzhou, Wuhan, Changsha, Shanghai, Tianjin
2024-04-07
Active, closed
TJ Biopharma Co., Ltd.
Phase 2/3
450
Anyang, Beijing, Bengbu, Binzhou, Changsha, Chongqing, Dongguan, Foshan
2024-03-28
Active, closed
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
42
Beijing, Bengbu, Changchun, Chengdu, Fuzhou, Zhengzhou, Zhongshan
2024-01-26
Active, closed
DualityBio Inc.
Phase 3
541
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-01-18
Recruiting
RemeGen Co., Ltd.
Phase 2
116
Bengbu, Beijing, Chongqing, Nanning, Changsha, Nanchang, Shenyang, Jinan
2024-01-11
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
68
Anyang, Bengbu, Changsha, Chengdu, Dongwan, Fuzhou, Guangzhou, Hangzhou
2024-01-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Bengbu, Hefei, Beijing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou
2023-12-31
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
270
Bengbu, Bozhou, Hefei, Beijing, Fuzhou, Dalian, Shanghai, Changzhi
2023-12-25
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
324
Bengbu, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Dalian
2023-12-19
Recruiting
AstraZeneca
Phase 3
1,145
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongwan, Fuzhou
2023-12-14
Recruiting
AstraZeneca
Phase 3
625
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-11-23
Recruiting
Amgen
Phase 3
750
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2023-11-16
Active, closed
AstraZeneca
Phase 3
1,902
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin
2023-11-14
Not yet open
Akeso
Phase 3
642
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou
2023-11-14
Recruiting
LeonaBio
Phase 3
600
Anhui, Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqicun
2023-10-31
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Beijing, Bengbu, Chengde, Chengdu, Jiaxing, Jinan, Nanchang, Nanyang
2023-10-12
Active, closed
AstraZeneca
Phase 3
5,511
Baoding, Beijing, Bengbu, Binzhou, Cangzhou, Changchun, Changsha, Chengdu
2023-10-05
Not yet open
Betta Pharmaceuticals Co., Ltd.
Phase 1
172
Bengbu, Changsha, Shanghai
2023-09-01
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Bengbu, Chongqing, Guangdong, Zhengzhou, Wuhan, Suzhou, Shanghai, Chengdu
2023-08-31
Recruiting
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3
248
Beijing, Shanghai, Bengbu, Changsha, Chongqing, Guizhou, Hangzhou, Henan
2023-08-12
Active, closed
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Active, closed
AbbVie
Phase 3
1,014
Bengbu, Beijing, Xiamen, Guangzhou, Shantou, Nanning, Luoyang, Wuhan
2023-07-25
Recruiting
LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer
NCT05923255Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer
Zhejiang University
Not applicable
568
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-05-14
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
480
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning
2023-05-10
Not yet open
Suzhou Puhe Pharmaceutical Technology Co., LTD
Phase 3
350
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2023-05-01
Active, closed
RemeGen Co., Ltd.
Phase 3
318
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou
2023-04-28
Active, closed
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 3
94
Bengbu, Beijing, Fuzhou, Guangzhou, Guiyang, Zhengzhou, Enshi, Wuhan
2023-04-27
Active, closed
The First Affiliated Hospital of Bengbu Medical University
Early Phase 1
15
Bengbu
2023-03-30
Active, closed
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Recruiting
Shanghai Institute Of Biological Products
Phase 1
36
Bengbu
2023-03-03
Active, closed
Taizhou Hanzhong biomedical co. LTD
Phase 3
190
Bengbu, Fuyang, Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou
2023-02-28
Active, closed
Bristol-Myers Squibb
Phase 3
516
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Baoding, Luoyang, Zhengzhou
2023-01-12
Recruiting
TR64 in Patients With Advanced Solid Tumors
NCT05649345Advanced Solid Tumor
Tarapeutics Science Inc.
Phase 1
19
Bengbu, Shenyang
2023-01-12
Active, closed
AstraZeneca
Phase 3
1,174
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2022-11-28
Active, closed
InxMed (Shanghai) Co., Ltd.
Phase 1/2
140
Hangzhou, Bengbu, Changsha, Fuzhou, Ganzhou, Nanjing, Wuhan, Xuzhou
2022-10-12
Recruiting
Teligene US
Phase 2
128
Bengbu, Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2022-09-01
Active, closed
AstraZeneca
Phase 3
341
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2022-08-03
Active, closed
AstraZeneca
Phase 4
43
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-07-29
Active, closed
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
Active, closed
Hoffmann-La Roche
Phase 3
922
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou
2022-07-18
Active, closed
AstraZeneca
Phase 1/2
119
Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-07-11
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
432
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei, Guangzhou
2022-07-01
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
82
Bengbu, Guangzhou, Guilin, Wuhan, Yueyang, Changchun, Hangzhou
2022-05-20
Active, closed
A Study of AL8326 in Non-Small Cell Lung Cancer
NCT06794957Non-small Cell Lung Cancer
DrugAL8326
Advenchen Laboratories, LLC
Phase 1
158
Bengbu, Hefei, Xuancheng, Anyang, Zhengzhou, Wuhan, Nanjing, Hangzhou
2022-05-19
Active, closed
Shanghai Henlius Biotech
Phase 3
511
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guilin
2022-05-17
Active, closed
AstraZeneca
Phase 3
644
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-05-16
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
NCT05294731B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
146
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Nanyang
2022-05-06
Active, closed
Shanghai Henlius Biotech
Phase 3
900
Bengbu, Hefei, Lu'an, Ma’anshan, Wuhu, Beijing, Chongqing, Chongqi
2022-04-25
Active, closed
Eli Lilly and Company
Phase 3
925
Bengbu, Hefei, Wuhu, Beijing, Guangzhou, Harbin, Wuhan, Changsha
2022-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan
2022-03-15
Active, closed
Laekna Limited
Phase 3
256
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Foshan, Guangzhou, Zhongshan
2022-02-18
Active, closed
AstraZeneca
Phase 3
363
Beijing, Bengbu, Chengdu, Guangzhou, Haikou, Hangzhou, Jinan, Jining
2022-02-15
Active, closed
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734Gastric or Esophagogastric Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
878
Bengbu, Chizhou, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2022-02-10
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Beijing, Bengbu, Changde, Changzhou, Chifeng, Daqing, Foshan, Guangzhou
2022-02-07
Recruiting
DualityBio Inc.
Phase 1/2
796
Bengbu, Hefei, Beijing, Hongcun, Chongqing, Xiamen, Lanzhou, Guangzhou
2022-01-31
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Bengbu, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Ganzhou
2022-01-19
Recruiting
Genor Biopharma Co., Ltd.
Phase 3
350
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Wenzhou, Xiamen, Foshan
2022-01-14
Recruiting
The First Affiliated Hospital of Bengbu Medical University
Phase 2
128
Bengbu
2022-01-14
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Bengbu, Changsha, Chengdu, Dongguan, Fuzhou, Guangzhou, Jinan, Linyi
2021-12-10
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Beijing, Bengbu, Changsha, Changzhi, Changzhou, Chengdu, Fuzhou, Guangzhou
2021-12-02
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Bengbu, Dongguan, Guangzhou, Changsha, Chengdu
2021-11-26
Active, closed
argenx
Phase 3
173
Beijing, Bengbu, Huizhou, Shenzhen, Tianjin, Wuhan, Wuxi, Zhengzhou
2021-11-17
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
DrugsEnvafolimab·Sunitinib·Lenvatinib
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Active, closed
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
NCT04684108Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
DrugSG301
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
61
Bengbu, Beijing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Xiangyang, Wuxi
2021-11-04
Active, closed
AstraZeneca
Phase 3
732
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou
2021-10-18
Active, closed
Boehringer Ingelheim
Phase 1
151
Bengbu, Changsha, Fuzhou, Guangzhou, Wuhan
2021-10-18
Active, closed
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Recruiting
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
NCT04930432Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
DrugMCLA-129
Betta Pharmaceuticals Co., Ltd.
Phase 1/2
400
Baoding, Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chifeng
2021-09-24
Not yet open
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
2,150
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Foshan, Guangzhou
2021-09
Recruiting
Yan Yang, MD, Ph.D
Phase 2
100
Bengbu
2021-08-21
Active, closed
Sun Yat-sen University
Phase 2
150
Bengbu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai
2021-07-21
Active, closed
Bristol-Myers Squibb
Phase 3
729
Bengbu, Beijing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Changzhou, Nanjing
2021-07-15
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-24
Active, closed
Janssen Research & Development, LLC
Phase 3
1,054
Baoding, Baotou, Beijing, Bengbu, Changchun, Changzhou, Chengdu, Chongqing
2021-06-17
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
663
Bengbu, Hefei, Jiangmen, Shenzhen, Shijiazhuang, Anyang, Xinxiang, Zhengzhou
2021-05-12
Active, closed
AstraZeneca
Phase 3
893
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2021-05-10
Recruiting
Sellas Life Sciences Group
Phase 1/2
160
Bengbu, Hefei, Chongqing, Guangzhou, Baoding, Zhengzhou, Suzhou, Nanchang
2021-05-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Bengbu, Beijing, Chongging, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou
2021-04-14
Recruiting
HANGZHOU Solution in Bicuspid AS Undergoing TAVR
NCT04722796Aortic Stenosis, Aortic Stenosis With Bicuspid Valve
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
508
Bengbu, Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha
2021-04-12
Active, closed
AstraZeneca
Phase 3
1,371
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian
2021-01-28
Recruiting
Pfizer
Phase 3
2,100
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Shenzhen, Haikou, Shijiazhuang
2021-01-15
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen
2020-12-02
Active, closed
AstraZeneca
Phase 3
640
Anyang, Beijing, Bengbu, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou
2020-10-19
Active, closed
Hoffmann-La Roche
Phase 3
992
Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Fujian, Guangzhou
2020-10-09
Active, closed
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
320
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guangxi, Haikou
2020-08-13
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
648
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2020-08-11
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2020-03-30
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2020-02-28
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 1
200
Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Weifang, Haerbin
2020-02-26
Active, closed
CStone Pharmaceuticals
Phase 3
534
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Foshan, Guangzhou, Nanning
2019-12-13
Active, closed
AstraZeneca
Phase 3
810
Baoding, Beijing, Bengbu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin
2019-04-16
Active, closed
AstraZeneca
Phase 3
1,407
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2019-01-04
Active, closed
AstraZeneca
Phase 3
407
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2018-11-27
Active, closed
AstraZeneca
Phase 3
730
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2018-09-27
Recruiting
The First Affiliated Hospital of Bengbu Medical University
Phase 2
30
Bengbu
2017-09-07
Recruiting
The First Affiliated Hospital of Bengbu Medical University
Observational
400
Bengbu
2017-06-04
Active, closed
AstraZeneca
Phase 3
987
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Hangzhou, Hefei
2017-03-27
Active, closed
AstraZeneca
Phase 3
669
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou
2017-01-02
Recruiting
The First Affiliated Hospital of Bengbu Medical University
Phase 2
120
Bengbu
2017-01
Active, closed
Eli Lilly and Company
Phase 3
463
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2016-12-05
Rows per page Showing 1–219 of 219
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/bengbu

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 219 of those studies with a site in Bengbu.

How many clinical trials are recruiting in Bengbu?

118 of the 219 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 17 have not yet opened recruitment, 82 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bengbu), 219 studies
PhaseStudiesRecruitingShare
Phase 31215155.3%
Phase 1221410%
Phase 1/220159.1%
Phase 219158.7%
Not applicable1576.8%
Phase 2/31074.6%
Observational652.7%
Early Phase 1321.4%
Phase 4321.4%

Most active sponsors

Lead sponsors with the most studies (Bengbu)
Lead sponsorStudiesRecruiting
AstraZeneca3413
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.115
The First Affiliated Hospital of Bengbu Medical University107
Merck Sharp & Dohme LLC62
Eli Lilly and Company52
Shanghai Henlius Biotech53
Beijing InnoCare Pharma Tech Co., Ltd.44
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.44
DualityBio Inc.41
Hoffmann-La Roche42
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.